摘要
目的探讨进展期胃肠道肿瘤术中使用雷替曲塞腹腔灌注化疗的安全性和疗效。方法选择48例进展期胃肠道肿瘤患者随机分为A、B两组,B组采用常规开腹手术治疗,A组行常规开腹手术+术中雷替曲塞腹腔灌注治疗。比较两组患者血常规、肝肾功能的变化,观察术后并发症发生情况及胃肠道功能恢复时间及2年生存率。结果两组术后白细胞计数、肝肾功能比较无统计学差异,术后两组腹腔引流时间、胃肠道功能恢复时间、并发症及不良反应发生率无统计学差异(P>0.05),A组术后1年及2年生存率高于B组(P<0.05)。结论进展期胃肠道肿瘤术中雷替曲塞腹腔灌注化疗安全有效,联合术后辅助化疗可提高患者的2年生存率。
Objective To investigate the safety and efficacy of intraperitoneal perfusion chemotherapy with rahitrexed in the surgery of advanced gastrointestinal cancer. Methods 48 patients with advanced gastrointestinal tumors who were selected and divided into two groups, group B was given routine open surgery, and group A was given routine open surgery+intraoperative intraperitoneal perfusion of rahitrexed. The changes of blood routine test, and liver and kidney function between two groups were compared. The postoperative complications, the recovery time of gastrointestinal function and two-year survival rate were observed. Results There was no statistically significant difference in white blood cell count and liver and kidney function between the two groups after surgery. There was no statistically signifi- cant difference in the time of abdominal drainage, recovery time of gastrointestinal function, complications and adverse reactions between the two groups(P〉0.05). The 1-year and 2-year survival rates in the group A were higher than those in the group B(P〈0.05). Conclusion Intraperitoneal perfusion chemotherapy with rahitrexed is safe and effective in the surgery of advanced gastrointestinal tumor. Combined postoperative adjuvant chemotherapy can improve the 2-year sur- vival rate of patients.
作者
苗志国
罗志鹏
黄凯
吴芳庚
MIAO Zhiguo;LUO Zhipen;HUANG Kai;WU Fanggen(Department of Abdominal Oneology Surgery,Jiangxi Provincial Cancer Hospital,Nanehang 330029,China;De-partment of Pathology,Jiangxi Provincial Cancer Hospital,Nanehang 330029,China)
出处
《中国现代医生》
2018年第25期10-12,共3页
China Modern Doctor
基金
江西省卫生计生委科技计划资助(20175411)
关键词
胃肠道肿瘤
雷替曲塞
腹腔化疗
安全性
Gastrointestinal tumor
Rahitrexed
Intraperitoneal chemotherapy
Safety